Aging on HRT¶
Most published transfeminine HRT data covers one to five years. The patients who started in the 2000s are now hitting 20-year marks, and a thin band who began in the 1990s or earlier are navigating their 60s and 70s on long-term estrogen. Long-term outcomes broadly look like cisgender female aging with transfeminine-specific caveats — soft-tissue feminization continues maturing for a decade, FFS bone work is permanent while soft-tissue adjuncts are not, estrogen-saturated skin ages along a premenopausal trajectory, and late-life dosing is converging slowly toward the conservative posture used for postmenopausal cis HRT.
The cohort age problem
Almost every cited mean is calculated on patients who started HRT at 30–45 and are 50–65 now. Anyone planning around the 70+ horizon is extrapolating from the Amsterdam ENIGI cohort, smaller European registries, and clinician experience. The next decade will produce the data this section needs.
Soft-tissue redistribution past the acute phase¶
Klaver 2017/2018 captures months 3–24, when gynoid fat percentage rises by roughly a third and waist-to-hip ratio drops about 0.03. After year two, the Wiepjes Amsterdam Cohort of Gender Dysphoria (n=2,627) suggests gynoid fat continues to accumulate slowly through year five, plateaus through year ten, and drifts back toward android distribution from roughly year 15 — paralleling the perimenopausal-to-postmenopausal transition. The shift is not a reversal of feminization; it is age-related visceral creep on an already-feminized baseline.
Fat-pad evolution by decade¶
| Region | Years 0–5 | Years 5–15 | Years 15+ |
|---|---|---|---|
| Gluteofemoral (hips, outer thighs) | Primary acute redistribution target | Largely persists with gradual softening | Most durable feminizing depot |
| Buccal / malar | Slight gain in early years | Begins thinning by late 40s | Mid-face hollowing; filler/fat-graft demand |
| Submental / jowl | Stable | Enlarges past 50, as in cis aging | Reads female on a feminized skeleton |
| Periorbital | Stable | Herniation begins | Eyelid bags, tear-trough deepening |
| Breast (gland + fat) | 48.7% under AAA at 12 mo (de Blok 2018); modest extra growth in 15–25% through year 5 | Imaging indistinguishable from cis women by year 10 (Sonnenblick 2018) | Measurable ptosis by year 10, substantial by year 20 |
| Visceral / android | Drops in year 1 | Slow plateau | Returns from year 15 onward |
Body composition layers on top. The age-related lean-mass loss every adult experiences (≈3–8% per decade past 40) compounds with the modest HRT-induced loss (≈2–3 kg in year one, plateauing thereafter) to produce sarcopenia risk by the late 60s in patients who do not resistance-train. Wiik/Lundberg's Karolinska MRI work showed thigh muscle volume −7% at five years, stable thereafter — but no transfeminine cohort has imaged past year ten.
BMD is the clinically heavy late-life endpoint
The Amsterdam group has shown adequate estradiol maintains BMD comparable to premenopausal cis women through at least 15 years. Patients who underwent orchidectomy and later under-dose or interrupt estrogen are at meaningful osteoporosis risk (Van Caenegem 2012 and ENIGI follow-ups). DXA every 2–3 years past 60 — or earlier if any HRT interruption has occurred post-orchi — is reasonable practice.
Skin aging on long-term estrogen¶
Estrogen drives dermal collagen synthesis, hyaluronic acid production, sebaceous activity, and capillary density. On HRT, sebum drops sharply within the first year, pore size shrinks, dermal thickness increases, and the changes the community calls "hormone skin" appear within months. The decade-scale question is whether the protective effect persists.
The cisgender comparison is the relevant frame. Premenopausal cis women lose collagen at roughly 1–2% per year from the late 20s; postmenopausal cis women lose 30% of dermal collagen in the first five years after menopause (Brincat 1987). Transfeminine patients on continuous adequate estrogen do not experience the postmenopausal collagen cliff — they continue along the premenopausal slope indefinitely. The clinical impression in long-followed cohorts is that 60-year-old trans women on continuous estrogen have skin closer to a 50-year-old cis woman's than to a 60-year-old's, particularly in dermal thickness and elasticity.
Photoaging and intrinsic chronological aging proceed normally. Solar elastosis, lentigines, actinic keratoses, telangiectasias, and dynamic rhytides are not prevented by estrogen and become the dominant aesthetic concerns by year 15. Sun protection, retinoids, and the standard anti-aging toolkit work the same way they work in cis female skin. See Skin for the active care toolkit.
Hair patterns deserve a separate note because they are the longest-followed aesthetic outcome. 5α-reductase inhibitor experience past ten years is mostly extrapolated from cis male AGA cohorts (Rossi 2016 and post-marketing finasteride data now extending past 25 years). In transfeminine patients on estradiol-suppressed androgens plus 5-ARI, the Amsterdam group reports gradual density gains continuing past year five and sometimes year ten in patients who started before extensive Norwood progression. Patients who started 5-ARI after substantial loss tend to plateau and rely on transplantation for further gain. Body and facial hair on long-term anti-androgen therapy continues to thin slowly past year five, but full clearance still requires laser or electrolysis even after a decade. See Hair and Anti-androgens.
How FFS results age¶
FFS has been clinically widespread for roughly 30 years, but published durability data is thin. Capitán/Simon, Deschamps-Braly, and Spiegel have begun publishing 5- and 10-year follow-ups, and a small revision-FFS literature is appearing. See FFS Overview for the procedural side.
Durability by procedure category¶
| Procedure | At 10 years | At 20 years | Revision driver |
|---|---|---|---|
| Frontal cranioplasty (type 3 setback) | No measurable regression on CT (Capitán 2014, Capitán/Simon 2020) | Bone-stable; soft-tissue brow descent overlays | Soft-tissue brow lift, not bone redo |
| Supraorbital rim, mandibular angle, gonial reduction, genioplasty | Bone-stable | Bone-stable | Soft-tissue aging on the corrected skeleton |
| Le Fort osteotomies | Healed and integrated | Stable | Rare; usually orthognathic complications |
| Lip lift (subnasal bullhorn) | Essentially permanent — skin excision does not regrow | Banks against age-related upper-lip lengthening | Refinement, scar revision |
| Rhinoplasty (bone) | Permanent | Permanent | — |
| Rhinoplasty (cartilage / soft tissue) | Mostly durable | Some reports of minor tip droop | Tip refinement |
| Fat grafting | Surviving fraction (30–60%) behaves as native fat | Ages with the face; volume loss reads as graft "fading" | Re-grafting for mid-face deflation |
| Implants (chin, malar, custom PEEK) | Cumulative reoperation 5–10% by year 10 | Capsule contracture, edge thinning, rare extrusion | Replacement, removal, or conversion to graft |
| Lip filler (HA) | Requires top-up every 6–18 months | Decade of presence = ongoing appointments | Maintenance, not revision |
Bone is permanent; soft tissue is what ages
Patients pursuing FFS revision at year 10+ are mostly addressing soft-tissue aging on a permanently feminized skeleton — mid-face deflation, jowling, brow descent — not asking the surgeon to redo bone work. The surface aging reads as cis-female aging rather than as "FFS wearing off." Capitán's revision series and Deschamps-Braly's 10-year follow-ups are the clinically useful references.
Revision drivers at decade-plus, in rough order: (1) soft-tissue aging on the FFS-corrected face, addressed with fat grafting, mid-face lifts, deep-plane facelifts, and blepharoplasty; (2) revision of soft-tissue adjuncts whose original surgeon was less experienced (rhinoplasty refinement, lip-lift adjustment, scar revision); (3) occasionally further bone work, typically to address areas the first surgery did not fully feminize.
Late-life surgery candidacy¶
Patients who deferred GRS, FFS, or breast augmentation into their 60s and 70s — or who want revision in that window — face considerations the under-50 literature does not cover well.
Anesthesia and HRT. Age itself is a major thrombotic risk factor, which makes the perioperative VTE conversation more pressing in older patients. WPATH SOC-8 does not mandate stopping estrogen; the field has moved toward continuing estradiol through major surgery on transdermal or sublingual routes, holding oral estradiol for 2–4 weeks pre-op, and using mechanical and pharmacological VTE prophylaxis aggressively (Boskey 2019; Robinson 2021). Older patients with prior VTE, smoking, obesity, atrial fibrillation, or malignancy should have an individualized plan, often coordinated by hematology. Spironolactone interacts with anesthetic blood-pressure management and is usually paused around major surgery; CPA's hepatotoxicity and meningioma signals become more clinically relevant in older patients, and many clinicians transition older patients off CPA before elective surgery if not already done. See Cardiovascular Health for the route-and-risk framework.
Recovery is meaningfully slower past 60. Wound healing, anesthetic clearance, delirium risk, postoperative cognitive dysfunction, and deconditioning all worsen with age in roughly continuous fashion. There is no trans-specific late-life surgical-outcomes literature; the working assumption is that transfeminine patients age along cis-female surgical-risk curves with the additional VTE consideration above.
GRS past 65 is feasible but the calculus shifts
GRS is technically feasible past 65, and a meaningful number of long-deferring patients pursue it in their 60s with no regret. Surgical-mortality and major-complication numbers for older patients are not zero, however, and have not been carefully characterized in transfeminine series. The risk-benefit conversation should include realistic life-expectancy and quality-of-life framing, not just technical feasibility.
Voice changes with aging¶
Estrogen does not lower the voice; testosterone did, in adolescence, and HRT does not undo it. Trained voice patterns, practiced consistently for a year or more, become motor-learned and persist with relative stability — the analogy is to musical-instrument skills, which degrade slowly without practice but rarely disappear.
Aging exerts two effects on the trained transfeminine voice. Presbyphonia — age-related thinning of vocal-fold tissue and weakening of laryngeal musculature — affects all voices past 60, producing breathiness, reduced loudness, and pitch instability. Cis female voices tend to lower slightly with age; cis male voices rise slightly; transfeminine voices on continuous estrogen seem to track the cis-female pattern, though formal data is essentially absent. Dynamic pitch and resonance control also degrades, narrowing the high end of trained range — patients who comfortably spoke at 180–200 Hz at 40 may find 200+ Hz harder to sustain at 70.
Maintenance is the same as for cis professional voice users: hydration, vocal hygiene, ongoing SLP engagement where possible, and occasional refresher work. Patients who underwent voice surgery (Wendler glottoplasty, cricothyroid approximation, feminization laryngoplasty) generally retain the surgical pitch elevation indefinitely; small published series at 10+ years (Casado 2017; Kim 2019) report broad stability with some patients losing 10–20 Hz over decades, recoverable with renewed training.
Late-life HRT dose considerations¶
The prevailing question past 65 is whether to continue full feminizing doses, dose-reduce, or switch to a "physiological postmenopausal" regimen. There is no consensus and the data are sparse.
| Position | Reasoning | Typical practice |
|---|---|---|
| Continue full premenopausal target | Transfeminine patients are not menopausal; reducing dose imposes iatrogenic menopause with predictable bone, skin, mood, and CV consequences | Continue E2 100–200 pg/mL, especially for orchidectomized patients where E2 is the only sex steroid in play |
| Dose-reduce at 65–70 | Parallels cis postmenopausal HRT framework (lower doses, prefer transdermal); Endocrine Society 2017 gestures toward this without specifying ages | Move to E2 40–80 pg/mL on transdermal, continue indefinitely rather than stopping |
| Individualized risk-stratified | Age 65 is not magical; dosing should track BMD, CV profile, VTE history, breast-cancer risk, and patient preference | Continue full dose for low-risk patients; dose-reduce for high-risk; route matters more than dose |
Route matters more than dose past 60
Oral estradiol's first-pass hepatic effects on coagulation factors become clinically meaningful as background VTE risk rises with age. Transdermal is increasingly the default past 50 in modern protocols regardless of dose. This is the single most consequential late-life dosing change — more than absolute E2 target.
Anti-androgens past 65 are usually reduced or stopped. Spironolactone's interactions with the medications older patients commonly take (ACE inhibitors, ARBs, NSAIDs, lithium) plus its hyperkalemia risk in the context of age-related GFR decline argue for tapering. Patients who underwent orchidectomy do not need anti-androgens at any age. Cyproterone acetate's meningioma risk, hepatic risk, and prolactin effects argue for discontinuation by the late 60s in essentially all patients still on it.
The honest data limitation is that no randomized trial has compared dosing strategies in transfeminine patients past 65, and the cohorts that exist are still mostly under 60. Until the next decade of follow-up arrives, late-life dosing is a clinical judgment call informed by cis postmenopausal HRT science, the patient's specific risk profile, and the patient's stated priorities.
Sources¶
- Wiepjes CM et al. The Amsterdam Cohort of Gender Dysphoria Study (1972–2015): trends in prevalence, treatment, and regrets. J Sex Med 2018; 15(4):582–590.
- Klaver M et al. Changes in regional body fat, lean body mass and body shape in trans persons using cross-sex hormonal therapy: results from a multicenter prospective study. Eur J Endocrinol 2018; 178:163–171.
- Klaver M et al. Cross-sex hormone therapy in transgender persons affects total body weight, body fat and lean body mass: a meta-analysis. Andrologia 2017; 49(5).
- de Blok CJM et al. Breast development in transwomen after one year of cross-sex hormone therapy: results of a prospective multicenter study. J Clin Endocrinol Metab 2018; 103(2):532–538.
- de Blok CJM et al. Breast cancer risk in transgender people receiving hormone treatment: nationwide cohort study in the Netherlands. BMJ 2019; 365:l1652.
- Sonnenblick EB et al. Breast imaging of transgender individuals: a review. Curr Radiol Rep 2018; 6(1):1.
- Van Caenegem E et al. Bone mass, bone geometry, and body composition in female-to-male transsexual persons after long-term cross-sex hormonal therapy. J Clin Endocrinol Metab 2012; 97(7):2503–2511.
- Wiik A, Lundberg TR et al. Muscle strength, size, and composition following 12 months of gender-affirming treatment in transgender individuals. J Clin Endocrinol Metab 2020; 105(3):e805–e813.
- Brincat M et al. Skin collagen changes in postmenopausal women receiving estradiol gel. Maturitas 1987; 9(1):1–5.
- Capitán L et al. Facial feminization surgery: the forehead. Surgical techniques and analysis of results. Plast Reconstr Surg 2014; 134(4):609–619.
- Capitán L, Simon D et al. Facial feminization surgery: a 10-year experience and outcomes. Aesthet Surg J 2020.
- Deschamps-Braly J. Facial feminization surgery: long-term outcomes and revision considerations. Clin Plast Surg 2018; 45(3):323–331.
- Spiegel JH. Facial determinants of female gender and feminizing forehead cranioplasty. Laryngoscope 2011; 121(2):250–261.
- Casado JC et al. Long-term results of glottoplasty in male-to-female transsexuals. Eur Arch Otorhinolaryngol 2017; 274(5):2199–2204.
- Kim HT. Vocal feminization for transgender women: current strategies and surgical outcomes. Ann Otol Rhinol Laryngol 2019.
- Hembree WC et al. Endocrine treatment of gender-dysphoric/gender-incongruent persons: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2017; 102(11):3869–3903.
- Coleman E et al. Standards of Care for the Health of Transgender and Gender Diverse People, Version 8. Int J Transgend Health 2022.
- Boskey ER et al. Perioperative considerations for transgender women on estrogen therapy. Transgender Health 2019.
- Robinson IS et al. Perioperative hormone management in gender-affirming surgery: a review. Plast Reconstr Surg 2021.
- Rossi A et al. Finasteride, 1 mg daily administration on male androgenetic alopecia: long-term safety. Dermatol Ther 2016; 29(5):349–354.